{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:10:41Z","timestamp":1793686241611,"version":"4.5.1"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T00:00:00Z","timestamp":1326153600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0030123","type":"journal-article","created":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T16:54:13Z","timestamp":1326214453000},"page":"e30123","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":162,"title":["Interleukin-1 Inhibition and Fatigue in Primary Sj\u00f6gren's Syndrome \u2013 A Double Blind, Randomised Clinical Trial"],"prefix":"10.1371","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct00683345","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Katrine Br\u00e6kke","family":"Norheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erna","family":"Harboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse G.","family":"G\u00f8ransson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roald","family":"Omdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,1,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sjogren&apos;s syndrome.","volume":"366","author":"RI Fox","year":"2005","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/03009742.2010.536164","article-title":"The point prevalence of clinically relevant primary Sjogren&apos;s syndrome in two Norwegian counties.","volume":"40","author":"L G\u00f8ransson","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1002\/art.11311","article-title":"Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren&apos;s syndrome.","volume":"48","author":"S Salomonsson","year":"2003","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/ard.2004.025676","article-title":"Primary Sjogren&apos;s syndrome: new clinical and therapeutic concepts.","volume":"64","author":"M Ramos-Casals","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"ref5","first-page":"283","article-title":"Primary Sjogren&apos;s syndrome: a subjective description of the disease.","volume":"8","author":"K Bjerrum","year":"1990","journal-title":"Clin Exp Rheumatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/rheumatology\/kep141","article-title":"Health-related quality of life, employment and disability in patients with Sjogren&apos;s syndrome.","volume":"48","author":"JM Meijer","year":"2009","journal-title":"Rheumatology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.bbi.2009.06.151","article-title":"Fatigue in primary Sjogren&apos;s syndrome\u2013a link to sickness behaviour in animals?","volume":"23","author":"E Harboe","year":"2009","journal-title":"Brain Behav Immun"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.rdc.2008.08.010","article-title":"Patient-reported outcomes including fatigue in primary Sjogren&apos;s syndrome.","volume":"34","author":"SJ Bowman","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/rheumatology\/keq009","article-title":"Primary Sjogren&apos;s syndrome: too dry and too tired.","volume":"49","author":"WF Ng","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/brbi.2000.0613","article-title":"Cytokine-induced sickness behavior: where do we stand?","volume":"15","author":"R Dantzer","year":"2001","journal-title":"Brain Behav Immun"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain.","volume":"9","author":"R Dantzer","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0149-7634(95)00037-F","article-title":"Mechanisms of sickness-induced decreases in food-motivated behavior.","volume":"20","author":"S Kent","year":"1996","journal-title":"Neurosci Biobehav Rev"},{"key":"ref13","first-page":"4447","article-title":"Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice.","volume":"12","author":"RM Bluthe","year":"2000","journal-title":"Eur J Neurosci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/eji.201040319","article-title":"IL-1: discoveries, controversies and future directions.","volume":"40","author":"CA Dinarello","year":"2010","journal-title":"Eur J Immunol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev.immunol.16.1.27","article-title":"Interleukin-1 receptor antagonist: role in biology.","volume":"16","author":"WP Arend","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-5728(94)90005-1","article-title":"Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier.","volume":"55","author":"EG Gutierrez","year":"1994","journal-title":"J Neuroimmunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bbi.2008.12.008","article-title":"Central inhibition of interleukin-1beta ameliorates sickness behavior in aged mice.","volume":"23","author":"J Abraham","year":"2009","journal-title":"Brain Behav Immun"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biological basis for interleukin-1 in disease.","volume":"87","author":"CA Dinarello","year":"1996","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4049\/jimmunol.156.1.389","article-title":"IL-1 beta does not cause neutrophil degranulation but does lead to IL- 6, IL-8, and nitrite\/nitrate release when used in patients with cancer.","volume":"156","author":"AC Ogilvie","year":"1996","journal-title":"J Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00296-004-0463-z","article-title":"The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis\u2013a pilot study.","volume":"25","author":"R Omdal","year":"2005","journal-title":"Rheumatol Int"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren&apos;s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.","volume":"61","author":"C Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000395074","article-title":"Assessment of depression: the depression inventory.","volume":"7","author":"AT Beck","year":"1974","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.","volume":"46","author":"LB Krupp","year":"1989","journal-title":"Arch Neurol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/art.24311","article-title":"Prevalence, severity, and predictors of fatigue in subjects with primary Sjogren&apos;s syndrome.","volume":"59","author":"B Segal","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.","volume":"67","author":"S Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/archneur.63.11.1612","article-title":"Peripheral neuropathy in primary sjogren syndrome: a population-based study.","volume":"63","author":"LG Goransson","year":"2006","journal-title":"Arch Neurol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1749-6632.1997.tb48395.x","article-title":"Central interleukin-1 receptors as mediators of sickness.","volume":"823","author":"KW Kelley","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.psyneuen.2007.10.008","article-title":"Identification and treatment of symptoms associated with inflammation in medically ill patients.","volume":"33","author":"R Dantzer","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.","volume":"355","author":"R Goldbach-Mansky","year":"2006","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1073\/pnas.1011774108","article-title":"Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system.","volume":"108","author":"A Hess","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bbi.2007.05.005","article-title":"Brain-immune communication pathways.","volume":"21","author":"N Quan","year":"2007","journal-title":"Brain Behav Immun"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000097202","article-title":"Passage of cytokines across the blood-brain barrier.","volume":"2","author":"WA Banks","year":"1995","journal-title":"Neuroimmunomodulation"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.1983.159","article-title":"Studies with different types of visual analog scales for measurement of pain.","volume":"34","author":"K Sriwatanakul","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren&apos;s syndrome: a randomized, double-blind, placebo-controlled trial.","volume":"62","author":"JM Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.","volume":"367","author":"S Tyring","year":"2006","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.pharmthera.2011.01.014","article-title":"Immune system to brain signaling: neuropsychopharmacological implications.","volume":"130","author":"L Capuron","year":"2011","journal-title":"Pharmacol Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.319.7211.703","article-title":"How to randomise.","volume":"319","author":"DG Altman","year":"1999","journal-title":"BMJ"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/acr.20173","article-title":"Accurate detection of changes in disease activity in primary Sjogren&apos;s syndrome by the European League Against Rheumatism Sjogren&apos;s Syndrome Disease Activity Index.","volume":"62","author":"R Seror","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0030123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T08:27:21Z","timestamp":1686644841000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0030123"}},"subtitle":[],"editor":[{"given":"Giuseppe","family":"Schillaci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,1,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0030123","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,10]]}}}